Longevity Startups

AdipoPharma is a French biotech company developing PATAS, a first-in-class stapled peptide insulin sensitizer that targets adipocytes to treat insulin resistance, type 2 diabetes, and associated comorbidities. Its adipocyte-focused approach aims to address the root cause of type 2 diabetes, with its lead drug entering clinical trials in 2025.

2 investors

Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision. It operates in the oncology and precision medicine space.

2 investors

AmyriAD Therapeutics is developing Ismidenon (formerly AD101), a once-daily oral small molecule therapy intended to improve cognition and function in patients with Alzheimer's disease. The drug uses a multi-modal approach to acetylcholine stimulation and is in preparation for a Phase 2/3 registration trial in the US.

2 investors

ANI.AI is a San Francisco research lab building a computational platform for longevity medicine that integrates deep multiomics, longitudinal digital phenotyping, and physician-supervised intervention into a unified model of an individual's biological state. It runs the ELITE healthspan intervention trial and an intervention layer (AgeBiotics) to make individual response to aging interventions measurable, working with research groups and clinical teams studying aging, cognition, muscle, immunity, metabolism, and microbiome.

2 investors

A company that develops and sells health products based on autophagy research, including its "Awa Bancha Autophagy 100" tea series aimed at supporting healthy longevity. It applies findings from autophagy science—the cellular self-degradation process linked to lifespan and aging—to consumer wellness products sold in Japan.

2 investors

Beads Hospice operates a residential facility in Japan that provides palliative and end-of-life care for patients with terminal cancer, neurodegenerative diseases, and other specified conditions. The facility offers home-like accommodations with medical and nursing support, combining hospice care with the continuation of residents' preferred lifestyles.

2 investors

Bevel is a consumer health app that synthesizes a user's health data from wearables to provide actionable insights and help individuals manage their own well-being. It emphasizes data interoperability across devices along with privacy and security for personal health information.

2 investors

Bevimi is a cognitive health company that develops nutritional supplements for brain health. Its first product, Uno Protect, is a single-dose liquid supplement using patent-pending liquid stabilization technology and 10 clinically dosed ingredients to support memory, focus, and long-term cognitive resilience.

2 investors

Biograph runs membership-based preventive health clinics that combine whole-body MRI, blood biomarkers, cardiac and brain imaging, DEXA scans and other diagnostics in a single-day assessment to detect early risk of heart disease, cancer, metabolic dysfunction and neurodegenerative disease. Physicians review the results with members and provide personalized recommendations and follow-up care, with clinics in San Mateo and New York City.

2 investors

BreezeBio develops a programmable platform called NanoGalaxy for targeted delivery of genetic medicines, aiming to move genetic payloads to specific cells and tissues. The company operates in the biotech and genetic therapeutics space.

2 investors

Bright Biotech produces recombinant proteins, including growth factors, by expressing them in plant chloroplasts. Its proteins are aimed at cell culture and regenerative medicine applications.

2 investors

Cambridge Nutraceuticals develops health supplements based on scientific research, aimed at supporting longer and healthier lives. The company operates in the nutraceuticals and consumer wellness space.

2 investors

CarePredict offers a platform that detects patterns in the daily activities of older adults to signal health changes and enable early intervention. It serves senior living operators and communities with data and tools to support resident well-being, staff efficiency, and proactive personalized care.

2 investors

CellRep uses AI to discover small molecules that rejuvenate immune cells without genetic modification, with a lead application enhancing CAR-T therapy against solid tumors. The compounds are applied ex vivo during manufacturing as reagents, building a platform for cellular rejuvenation spanning cancer immunotherapy and longevity.

2 investors

cellvie develops Therapeutic Mitochondria Transplantation, a technique that augments or replaces failing mitochondria to restore cellular energy metabolism, with initial applications in ischemia-reperfusion injury (starting with kidney transplantation) and in mitochondria-enabled gene therapy for the genetic skin disease Epidermolysis Bullosa. Its therapies target intractable human conditions including organ transplant injury, degenerative aging processes, and rare genetic diseases.

2 investors

Celularity is a regenerative and cellular medicine company developing and commercializing biomaterial products and allogeneic, cryopreserved cell therapies derived from the postpartum placenta to target age-related diseases. It operates its own integrated manufacturing, translational research, and biobanking facility for placenta-derived cellular medicines and advanced biomaterials.

2 investors

Clay is a concierge medicine practice offering health assessments, lifestyle guidance, and clinically managed medical care focused on longevity and optimal health. It provides insurance-supported, personalized health plans to individuals and groups in Nevada.

2 investors

Dia Beta Labs is a UK-based biotech company developing a pipeline of engineered therapeutic peptides that target beta-cell receptors to treat metabolic diseases such as Type 2 diabetes and obesity. Its candidates aim to preserve and restore pancreatic beta-cell health while supporting weight loss, and are currently in preclinical development.

2 investors

Different Health provides whole-body health assessments in which a team of MDs and PhDs analyzes 1,000+ biomarkers across cardiovascular, hormone, metabolic, nutrient, and inflammation categories to build personalized nutrition, training, and health plans. It offers in-person and virtual diagnostics, physician-led reviews, and 1:1 strength and conditioning coaching for individuals and for corporate teams via an onsite service.

2 investors

dNovo develops direct reprogramming technology to convert skin, blood, or fat cells into new stem cells, targeting age-related stem cell depletion. The company aims to address aging through cellular regeneration for consumers.

2 investors

Dorian Therapeutics was a biotechnology startup developing senoblockers, drugs designed to rejuvenate cells and tissues by targeting aging-related mechanisms. Acquired by Altos Labs.

2 investors

Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.

2 investors

Emerald offers comprehensive health testing (124 biomarkers), clinician-reviewed results, wearable and historical data integration, and ongoing care to help individuals identify metabolic, cardiovascular, and weight-related risks earlier. The service also includes weight management support and in-app GP chat access for proactive, preventive healthcare.

2 investors

Everlab is a digital health platform offering personalized preventative medicine and longevity testing across Australia, combining bloodwork diagnostics, genetic testing, and specialist access with an app-based care coordination system guided by longevity-trained doctors.

2 investors